Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
about
Intravenous and gastric cerium dioxide nanoparticle exposure disrupts microvascular smooth muscle signalingAntioxidants in Cardiovascular Therapy: Panacea or False Hope?Epidemiology of preeclampsia: impact of obesityDimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury.Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine.l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbitsAsymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.Effect of Controlling Hypercholesterolemia on Myocardial Ischemia.The Role of Obesity in Preeclampsia.Emerging therapeutic targets in nitric oxide-dependent cardiac disease.L-arginine in cardiovascular disease: dream or reality?The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.Mechanistic studies of inactivation of inducible nitric oxide synthase by amidinesArginase: a critical regulator of nitric oxide synthesis and vascular function.Impact of ADMA, endothelial progenitor cells and traditional cardiovascular risk factors on pulse wave velocity among prediabetic individuals.Endogenous inhibitors of nitric oxide and preeclampsia: a review.Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunctionArginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats.Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2.What are the metabolic precursors which increase the risk of pre-eclampsia and how could these be investigated further.Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine.Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in maternal and fetal circulation.Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading.Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation.Hyper-activation of pp60Src limits nitric oxide signaling by increasing asymmetric dimethylarginine levels during acute lung injury.Homocysteine and asymmetric dimethylarginine in relation to B vitamins in elderly people.Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors.
P2860
Q23923199-0FDC7916-6452-4061-9686-C0AE7DC1BCDFQ26776115-F0933849-370E-40C8-9210-7EA72B1BA16BQ27006497-0713720D-EB25-43C9-9191-C988360895D9Q33799650-433450EB-9744-4A93-9DE0-B5C8D0AB9242Q33889586-00C947D4-3E75-460B-824F-8685E4459E67Q34016071-C7DAB845-673D-41E2-8C54-FCF3CA23CA9BQ34201581-B0ED201C-D946-489C-A69A-F5DA41DEFC62Q34518020-5196116F-B46D-4323-8AB1-D599E1C346B5Q34853745-220256FE-1704-42BE-AE5D-6727887FD8C3Q35050418-8BBC61AC-5ABD-4968-BB98-46FDA4EB9D8BQ35055189-C6A5AF89-4395-4980-938B-15408CD6FBAAQ35055194-A5E9CAB1-76E1-4C4F-8670-E92FA978190FQ35540305-F1119FBC-0CC5-404F-94E4-65C3E961E11FQ35954810-05EBA8E7-4710-4822-A4B9-702053AE1F41Q36480527-81884A2C-3ACE-40F0-812A-FECE97D4557AQ36590924-7BDDC4A6-FCFF-4B08-8F3F-85911DE38D5AQ37274252-BAA52403-0CD2-4D43-9971-52AC2FA90D5EQ37391969-F13F93FF-9D74-4D66-AD1E-E0D5B4026C1DQ37824119-D6BC6427-03EB-4BF3-A972-BA5AFED7D753Q38601790-537BEE6B-A023-4C10-8D42-D78F1013E98FQ39321647-E28527C6-6350-415B-8E99-041B20CF0014Q44271946-4B7872F8-1BCE-40C1-B4C9-A39A15A22427Q44643140-A7DF02AF-5CC3-46CF-A7F3-E93C79495394Q44796931-31EBE6E3-F24C-4691-9FFF-98650B1402E5Q47100484-5EEFD15B-32C6-45A4-9611-D393163921F4Q51540654-8F2A091D-AB91-4662-8F3E-1094D440FAFCQ51552068-E77119F4-C2AC-439B-985D-6EE995017A37
P2860
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@ast
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@en
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@nl
type
label
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@ast
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@en
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@nl
prefLabel
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@ast
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@en
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@nl
P356
P1476
Asymmetric dimethylarginine, d ...... , and cardiovascular diseases.
@en
P2093
S M Bode-Böger
P304
P356
10.1055/S-2000-13210
P577
2000-01-01T00:00:00Z